CLINICAL TRIALS PROFILE FOR METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA

All Clinical Trials for methoxy polyethylene glycol-epoetin beta

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00090753 ↗	A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia	Completed	Hoffmann-La Roche	Phase 3	2004-10-01	This study assessed the long-term efficacy, safety, and tolerability of intravenous (iv) or subcutaneous (sc) methoxy polyethylene glycol-epoetin beta in chronic kidney disease patients with renal anemia. Eligible patients were those who were receiving stable maintenance therapy with methoxy polyethylene glycol-epoetin beta or erythropoiesis stimulating agents (ESAs) in Phase II or III clinical studies. They continued to receive methoxy polyethylene glycol-epoetin beta or comparator ESAs at the same weekly dose and by the same route of administration (sc or iv) as in the qualifying studies.
NCT00422513 ↗	A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.	Terminated	Hoffmann-La Roche	Phase 3	2007-03-01	This 2 arm study will compare 'time and motion' (provider time spent on anemia management) and effect on hemoglobin (Hb) levels, of methoxy polyethylene glycol-epoetin beta (Mircera) and epoetin alfa, in anemic patients with chronic kidney disease (CKD) on hemodialysis. Patients stable on intravenous (iv) epoetin alfa will be randomized either to receive standard of care therapy (epoetin alfa (iv) 3 times weekly), or to receive Mircera 120-360 micrograms (iv), monthly. After a titration period, average time spent on anemia treatment over a 3 month period will be evaluated. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
NCT00454246 ↗	A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.	Terminated	Hoffmann-La Roche	Phase 3	2007-04-01	This study will assess the efficacy and safety of methoxy polyethylene glycol-epoetin beta (Mircera) in the maintenance of hemoglobin levels in patients who have previously received treatment with epoetin alfa or darbepoetin alfa, and who are transitioning from chronic kidney disease stage 4 through dialysis. Patients will be randomized either to receive Mircera or to remain on their existing therapy; the initial monthly dose of subcutaneous (sc) Mircera (120-360 micrograms) will be based on the average weekly dose of epoetin alfa or darbepoetin alfa administered in the week preceding the switch to Mircera. At the initiation of dialysis, patients in the Mircera group will receive monthly intravenous (iv) Mircera at a starting dose based on their previous (sc) dose, and those in the control group will receive weekly (iv) epoetin alfa. The anticipated time on study treatment is 1-2 years, and the target sample size is 500+ individuals.
NCT00517881 ↗	Efficacy, Safety and Tolerability Study of Subcutaneous C.E.R.A. in Pre-Dialysis Participants With Chronic Renal Anemia	Terminated	Hoffmann-La Roche	Phase 3	2007-06-01	This single arm study will assess the efficacy, safety and tolerability of subcutaneous methoxy polyethylene glycol-epoetin beta (C.E.R.A.) for maintenance of hemoglobin levels in pre-dialysis participants with chronic renal anemia. Participants currently receiving maintenance treatment with subcutaneous darbepoetin alfa will receive monthly subcutaneous injections of C.E.R.A. with the starting dose of 120, 200 or 360 micrograms (mcg) derived from the dose of darbepoetin alfa or epoetin alfa in the week preceding study start.
NCT00605293 ↗	A Study of Intravenous Mircera (C.E.R.A or Methoxy Polyethylene Glycol-epoetin Beta) for the Maintenance Treatment of Hemodialysis Participants With Chronic Renal Anemia	Completed	Hoffmann-La Roche	Phase 3	2008-01-01	This 2 arm study will compare the efficacy and safety of monthly administration of intravenous (IV) Mircera versus epoetin alfa for the maintenance of hemoglobin levels in hemodialysis patients with chronic renal anemia. Participants currently receiving maintenance treatment with epoetin alfa will be randomized either to receive monthly injections of 120, 200 or 360 micrograms Mircera, with the starting dose derived from the dose of epoetin alfa they were receiving in the week preceding study start, or to continue on epoetin alfa treatment. The anticipated duration of study is 32 weeks, and the target sample size is 146 participants.
NCT00642668 ↗	A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia	Completed	Hoffmann-La Roche	Phase 4	2008-06-30	This single arm study assessed the efficacy and safety of subcutaneous methoxy polyethylene glycol-epoetin beta (Mircera), a continuous erythropoietin receptor activator (C.E.R.A.), for correction and/or maintenance of hemoglobin levels in participants with chronic kidney disease and renal anemia, who were not treated with erythropoiesis-stimulating agents (ESA) or on dialysis. Eligible participants received monthly subcutaneous injections of methoxy polyethylene glycol-epoetin beta at an initial recommended dose of 1.2 micrograms/kilogram (mcg/kg). The anticipated time on study treatment was 3-10 months, and the target sample size was 200 individuals.
NCT00642967 ↗	A Study of Subcutaneous Mircera for the Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis	Completed	Hoffmann-La Roche	Phase 3	2008-06-01	This single arm study will assess the efficacy and safety of monthly administration of subcutaneous methoxy polyethylene glycol-epoetin beta (Mircera) when administered for the maintenance of hemoglobin levels in participants with chronic renal anemia, not on dialysis. Participants currently receiving treatment with subcutaneous epoetin or darbepoetin alfa will receive monthly subcutaneous injections of methoxy polyethylene glycol-epoetin beta, with the starting dose (120 or 200 micrograms) calculated from the last weekly dose of epoetin beta or darbepoetin alfa previously administered.

Clinical Trial Conditions for methoxy polyethylene glycol-epoetin beta

Condition Name

Condition Name for methoxy polyethylene glycol-epoetin beta
Intervention	Trials
Anemia	21
Renal Anemia of Chronic Kidney Disease	2
Anemia of Chronic Kidney Disease	2
Anemia, Kidney Transplantation	1

Condition MeSH

Condition MeSH for methoxy polyethylene glycol-epoetin beta
Intervention	Trials
Anemia	21
Renal Insufficiency, Chronic	13
Kidney Diseases	12
Renal Insufficiency	2

Clinical Trial Locations for methoxy polyethylene glycol-epoetin beta

Trials by Country

Trials by Country for methoxy polyethylene glycol-epoetin beta
Location	Trials
United States	87
Italy	25
Spain	12
Australia	11
Germany	7

Trials by US State

Trials by US State for methoxy polyethylene glycol-epoetin beta
Location	Trials
Alabama	4
Virginia	4
Texas	4
Georgia	4
Florida	3

Clinical Trial Progress for methoxy polyethylene glycol-epoetin beta

Clinical Trial Phase

Clinical Trial Phase for methoxy polyethylene glycol-epoetin beta
Clinical Trial Phase	Trials
PHASE3	2
Phase 4	10
Phase 3	11

Clinical Trial Status

Clinical Trial Status for methoxy polyethylene glycol-epoetin beta
Clinical Trial Phase	Trials
Completed	24
Terminated	4
RECRUITING	3

Clinical Trial Sponsors for methoxy polyethylene glycol-epoetin beta

Sponsor Name

Sponsor Name for methoxy polyethylene glycol-epoetin beta
Sponsor	Trials
Hoffmann-La Roche	27
PT Kalbe Genexine Biologics	2
Hamad Medical Corporation	1

Sponsor Type

Sponsor Type for methoxy polyethylene glycol-epoetin beta
Sponsor	Trials
Industry	33
Other	1

Methoxy polyethylene glycol-epoetin beta Market Analysis and Financial Projection

Last updated: February 9, 2026

Clinical Trials Status and Updates for Methoxy Polyethylene Glycol-Epoetin Beta

Methoxy polyethylene glycol-epoetin beta (MPEG-Ep), marketed as Mircera by Roche, has completed multiple phases of clinical testing. Its primary indication is anemia associated with chronic kidney disease (CKD). Key phases are as follows:

• Phase III Trials: Demonstrated non-inferiority to darbepoetin alfa in correcting anemia, with similar safety profiles. Launched in Europe and other markets in 2009.
• Ongoing Studies: Includes post-marketing surveillance and investigations in specific subpopulations such as pre-dialysis CKD patients.
• Regulatory Approvals: Approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) in 2009 and 2010, respectively.

There are no publicly disclosed plans for new phase trials or significant clinical updates presently. The drug’s primary market has stabilized post-approval, with continued safety monitoring.

---

Market Overview and Competitive Landscape

Existing Market

• Estimated Market Size: The global anemia management market, which includes erythropoiesis-stimulating agents (ESAs), was valued at roughly USD 8.5 billion in 2021. It is expected to reach approximately USD 13.2 billion by 2027, growing at a compound annual growth rate (CAGR) of 7.0% (MarketWatch).

• Key Players: Main competitors are Amgen’s epoetin alfa (Epogen, Procrit), Roche’s Mircera, and Janssen’s darbepoetin alfa (Aranesp).

• Market Share (2022): Roche’s Mircera held approximately 20-25%, according to IQVIA data. It competes primarily in pre-dialysis and dialysis settings.

Market Drivers

• Rising prevalence of CKD, estimated to affect over 850 million globally.
• Increasing incidence of anemia related to chronic diseases.
• Adoption of long-acting ESAs, reducing injection frequency and improving patient compliance.

Market Challenges

• Safety concerns over ESA use, including thromboembolic risks at high hemoglobin targets.
• Competition from biosimilars, with several emerging candidates.
• Shifts in treatment guidelines towards more restrictive ESA use, affecting demand.

---

Market Projections and Future Trends

Short- to Medium-Term Projections (2023–2027)

Metric	Projection	Source
Market Value	USD 13.2 billion	MarketWatch
CAGR	7.0%	MarketWatch
MPEG-Epoetin Beta Market Share	20-25%, stable	IQVIA

Roche’s Mircera is expected to maintain steady demand due to its dosing convenience and established safety profile. However, growth may be tempered by the impact of biosimilar entrants and evolving guidelines.

Long-Term Outlook (2028 and beyond)

Market growth may slow as newer therapies emerge and tighter anemia management protocols are adopted. The potential for biosimilar erythropoietins to erode market share remains significant, especially in regions with generic drug policies.

Emerging alternatives include hypoxia-inducible factor (HIF) stabilizers, such as roxadustat, which may compete with ESAs by offering oral administration and different safety profiles.

---

Key Market Dynamics

• Regulatory Environment: Increasing focus on safety has led authorities to restrict ESA dosing targets, impacting sales volumes.
• Reimbursement Policies: Variability influences market penetration, particularly in low- and middle-income countries.
• Innovation: Long-acting formulations like Mircera are favored for reducing injection frequency.

---

Conclusion

Methoxy polyethylene glycol-epoetin beta remains a key product in anemia management for CKD but faces intensifying competition from biosimilars and novel treatments. Its market share is stable but unlikely to expand significantly without new clinical indications or formulations.

---

Key Takeaways

• Mircera achieved regulatory approval in 2009-2010, with clinical trials confirming efficacy and safety comparable to other ESAs.
• The global anemia management market is projected to grow at about 7% annually through 2027, with Mircera maintaining a 20-25% share.
• Biosimilars and HIF stabilizers pose long-term threats, possibly eroding market share.
• Market growth may slow due to regulatory restrictions on ESA use and safety concerns.
• Roche’s strategic focus will likely involve dose optimization, expanding indications, or pipeline development.

---

FAQs

1. What are the main clinical advantages of methoxy polyethylene glycol-epoetin beta?
It has a longer half-life than traditional epoetins, requiring fewer injections and improving patient compliance.

2. How does Mircera compare to its competitors?
It offers similar efficacy and safety to darbepoetin alfa but is preferred in some markets for dosing convenience.

3. Are biosimilars impacting the market?
Yes, several biosimilars have entered the market in regions like Europe, exerting downward pressure on prices and market share.

4. What future developments could influence the market?
Introduction of HIF stabilizers and new formulations could reduce demand for traditional ESAs like Mircera.

5. What regions are most significant for Mircera sales?
Europe and North America constitute the primary markets, with increasing adoption in Asia-Pacific and Latin America.

---

References

[1] MarketWatch. "Global Anemia Management Market Size, Share & Trends Analysis Report." 2022.
[2] IQVIA. "Global Biosimilar Market Data." 2022.
[3] European Medicines Agency. "Mircera Approvals." 2009.
[4] US FDA. "Mircera Approval Summary." 2010.